Now showing items 1-5 of 5
HER2 expression patterns in paired primary and metastatic endometrial cancer lesions
(Nature Publishing Group, 2017-11-23)
Background: Despite successful implementation of drugs targeting the human epidermal growth factor receptor 2 (HER2) receptor in breast and gastric cancers, the potential of HER2 as a therapeutic target in other cancers ...
Aneuploidy related transcriptional changes in endometrial cancer link low expression of chromosome 15q genes to poor survival
(Impact Journals, 2017)
Aneuploidy is a widely studied prognostic marker in endometrial cancer (EC), however, not implemented in clinical decision-making. It lacks validation in large prospective patient cohorts adjusted for currently standard ...
ATAD2 overexpression links to enrichment of B-MYBtranslational signatures and development of aggressive endometrial carcinoma
(Impact Journals, 2015)
We have explored the potential for clinical implementation of ATAD2 as a biomarker for aggressive endometrial cancer by investigating to what extent immunohistochemical (IHC) staining for ATAD2 is feasible, reflects clinical ...
High BMI is significantly associated with positive progesterone receptor status and clinico-pathological markers for non-aggressive disease in endometrial cancer
(Nature Publishing Group, 2011)
Background: Endometrial cancer incidence is increasing in industrialised countries. High body mass index (BMI, kg m−2) is associated with higher risk for disease. We wanted to investigate if BMI is related to ...
Switch in FOXA1 status associates with endometrial cancer progression
(Public Library of Science, 2014-05-21)
Background: The transcription factor Forkhead box A1 (FOXA1) is suggested to be important in hormone dependent cancers, although with little data for endometrial cancer. We investigated expression levels of FOXA1 in primary ...